Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24635820 | 1.00 | HTR2A (0.35) | HTR2APTPN11ADRA2AADRA2BADRA2C | |
| SCHEMBL23023953 | 1.00 | HTR2A (0.35) | HTR2APTPN11ADRA2AADRA2BADRA2C | |
| SCHEMBL30529555 | 1.00 | HTR2A (0.35) | HTR2APTPN11ADRA2AADRA2BADRA2C | |
| SCHEMBL22523738 | 1.00 | HTR2A (0.35) | HTR2APTPN11ADRA2AADRA2BADRA2C | |
| SCHEMBL23023952 | 1.00 | HTR2A (0.35) | HTR2APTPN11ADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL22493747 | 0.98 | HTR2A (0.34) | HTR2APTPN11 | |
| Hydrochloric Acid SCHEMBL31288462 | 0.98 | HTR2A (0.34) | HTR2APTPN11 | |
| SCHEMBL24335986 | 0.79 | SLC6A2 (0.35) | PTPN11 | |
| SCHEMBL21397424 | 0.76 | HTR2A (0.39) | HTR2A | |
| SCHEMBL21397423 | 0.76 | HTR2A (0.39) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340576-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340576-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | HTR2A 4480/4885PTPN11 14/4885ADRA2A 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.